Hemoglobin levels in people living with sickle cell disease are typically lower than the average person.
11 US sites
2 Canada sites
> 18 Years
SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
2
The THRIVE-132 study is determining the safety and efficacy of a single dose of inclacumab, an investigational therapy, as a possible treatment to prevent readmission to the hospital for a vaso-occlusive crises (VOCs) in individuals with sickle cell disease.
“The Electronic Patient Reported Pain Assessment in Sickle Cell” study aims to gather insights into painful crises in people living with sickle cell disease.
1 USA site
> 18 Years
SCD type SS, SCD type Sβ0 thalassemia
N/A
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.
The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.
> 12 Years
SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
3
